Fig. 5

Prognostic prediction by landmark MRD status. (A) Comparison of landmark ctDNA status between pCR and non-pCR patients. P values were calculated by Fisher’s exact test. (B) Kaplan-Meier (K-M) curves between patients with different landmark ctDNA status for DFS. P values were calculated by log-rank test and HR were estimated by Cox proportional hazards model. (C) K-M curves for DFS analysis between patients stratified by pCR and landmark ctDNA status. P values were calculated by log-rank test. (D) Coefficients of multivariable Cox model with clinical risk factors and landmark ctDNA status. (E) Statistics of NPV and PPV for recurrence prediction by MRD at preoperative and landmark timepoints. (F) Comparison of landmark ctDNA status in different postoperative pathological stage of tumor. P values were calculated by Fisher’s exact test. (G) K-M curves for DFS analysis between patients stratified by ctDNA status from preoperative to landmark timepoint including consistent negative, converted positive and consistent positive. P values were calculated by log-rank test. (H) Comparison of patients stratified by ctDNA status from preoperative to landmark timepoint in different postoperative pathological stage of tumor. P values were calculated by log-rank test